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Objective: To estimate first-year treatment costs among new initiators of topical prostaglandin 
analogs in a managed care population.
Research design and methods: A model was developed to estimate first-year medical 
costs. Model inputs were based on weighted results from three previous studies. Treatment 
patterns were derived from a claims database analysis. Published studies were used to estimate 
  visit-related resource use. Costs were obtained from standard sources.
Results: Across studies, 27,809 patients met study criteria, 44.2% of whom remained on their 
index therapy for 12 months. Adjunctive therapy was needed in 22.5%, 18.5%, and 11.9% of 
bimatoprost, latanoprost, and benzalkonium chloride (BAK)-free travoprost patients,   respectively. 
Median days to initiating adjunctive therapy were 64, 67, and 127 for bimatoprost, latanoprost, 
and BAK-free travoprost patients. Estimated first-year medical costs were $1,945, $1,803, and 
$1,730 for patients initiating therapy with bimatoprost, latanoprost, and BAK-free travoprost. 
Findings were consistent through sensitivity analysis.
Conclusions: A BAK-free prostaglandin analog may permit longer duration of monotherapy 
and be associated with lower first-year treatment costs. Use of a claims database and the 
selection of new initiators of prostaglandin analogs limit the ability to project findings to all 
glaucoma patients.
Keywords: costs and cost analysis, drug therapy, combination, glaucoma, prostaglandin 
analogs
Introduction
Across studies of treatments for primary open-angle glaucoma (POAG), it is clear 
that there are many challenges to achieving and maintaining maximum reduction 
of intraocular pressure (IOP) and delaying disease progression. One challenge is 
increasingly complex regimens, known to be problematic for adherence in glaucoma 
treatment and across all chronic diseases.1–3 Proper instillation of eyedrops also cannot 
be assumed.2,4,5 Another is the presence of adverse events, such as the development 
of ocular surface disease (OSD),3 that can affect adherence.6 In fact, approximately 
half of glaucoma patients experience some signs and/or symptoms of OSD in at least 
one eye.7,8
Given these impediments to adherence, the logical treatment should be a 
  monotherapy with once daily dosing and a low likelihood of adverse events. However, 
even highly effective glaucoma therapies may not be sufficient to achieve adequate 
IOP reduction.9–11 Prostaglandin analogs, which are recommended as first-line therapy 
for POAG by the American Academy of Ophthalmology,12 often require the use of Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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adjunctive therapies, increasing exposure to preservatives 
commonly found in ophthalmic solutions. This increased 
exposure may decrease the success of filtration surgery if 
needed to treat more severe disease.13 A key question is 
whether there are differences among these recommended 
therapies, and a series of studies suggests that there may be 
one differentiating factor.
Of the three topical prostaglandin analogs currently 
approved and available in the United States, only travoprost 
is available without the preservative BAK. This newer 
  product, BAK-free travoprost, is comparable in   concentration 
to the conventional travoprost (including BAK) and has 
demonstrated equivalent IOP-lowering efficacy compared 
to travoprost with BAK.14 Furthermore, additional studies 
suggest that transitioning patients from a BAK-containing 
prostaglandin analog to BAK-free travoprost may improve 
ocular surface health, as indicated by signs and symptoms of 
OSD.15–21 Three studies explored the impact on use and type 
of adjunctive therapy and annual costs for patients   initiating 
glaucoma therapy with prostaglandin analogs.22–24 Each study 
used the same inclusion criteria and identified patients with 
a prescription for a topical prostaglandin analog during a 
  six-month period who had no glaucoma therapy claims in the 
six months prior and had at least 12 months of data available 
after the initial prostaglandin analog claim. Thus the   analyses 
are comparable, although costs were updated to current values 
at the time each study was conducted.
The first study in the series24 compared treatment 
  patterns and estimated annual costs of patients newly 
  initiating therapy with one of three prostaglandin analogs: 
  bimatoprost, latanoprost, or the BAK-free travoprost. 
  Significantly fewer patients using BAK-free travoprost 
required   adjunctive therapy compared to the other treat-
ments, and the duration of monotherapy was twice as long 
for BAK-free   travoprost (109 days) compared with the 
shortest duration of   monotherapy identified (bimatoprost, 53 
days). In addition, costs were approximately 11% lower for 
patients initiating therapy with BAK-free travoprost ($1,160) 
compared with the comparator with the highest first-year 
costs (  bimatoprost, $1,294). The second study in the series23 
also found BAK-free travoprost associated with rates of 
  adjunctive therapy use of less than half of comparators (8.9% 
vs 16.5% for   latanoprost and 20.7% for   bimatoprost) and 
duration of   monotherapy   significantly lower than   comparators 
(158.5 days vs 69.5 days for bimatoprost and 67.0 days for 
latanoprost). The   differential in costs remained approximately 
11%, with first-year costs for BAK-free travoprost estimated 
to be $1,307 compared with the highest cost of $1,457 for 
bimatoprost. Finally, the third study in the series22 found that 
adjunctive intraocular pressure lowering therapy was needed 
in 23.6%, 18.5%, and 13.3% of bimatoprost, latanoprost, and 
BAK-free travoprost patients, respectively. Median numbers 
of days to the first prescription filled for adjunctive therapy 
(if required) were 72.5, 74.0, and 125.0 for patients initiating 
on bimatoprost, latanoprost, and BAK-free travoprost. Total 
estimated   first-year costs were $1,973, $1,807, and $1,739 
for patients initiating therapy with bimatoprost, latanoprost, 
and BAK-free travoprost.
The present study pooled data across all three studies, 
looking at 18 months of data on FDA-approved   prostaglandin 
analogs.
Methods
We used three primary sources of input into the economic 
model. We first conducted multiple retrospective cohort 
  studies, over time, using a prescription benefits database.22–24 
Data from these analyses were pooled and were used to 
  identify the population of patients receiving   prostaglandin 
analogs and to explore patterns of use of adjunctive 
  therapies. Second, we reviewed published studies identified 
through a literature review to estimate the components of a 
typical outpatient visit (initial evaluation, diagnostics tests, 
and   follow-up care). Finally, we consulted standard cost 
sources to provide costs for each resource (initial treatments, 
  adjunctive therapies, and visits) identified.
Database analysis: study population  
and use of adjunctive therapies
The patients described in the retrospective cohort analysis 
were receiving prescription benefits and were included in a 
prescription claims database of a large   pharmaceutical   benefits 
manager (PBM). This PBM serves more than 75   million 
plan participants across the United States. All data were 
  de-identified in accordance with Protected Health   Information 
standards under the Health Information   Portability and 
Accountability Act so that no individually identifiable infor-
mation was included in the study database. Therefore, review 
by an institutional review board was not required.
The study cohort included patients who first initiated 
therapy with one of three prostaglandin analog products 
(bimatoprost, latanoprost, or BAK-free travoprost) between 
November 1, 2006 and April 30, 2008. To qualify for each of 
the previous three studies, patients had to have more than one 
prescription claim of their index prostaglandin analog and six 
months of prior claims data in which there were no glaucoma 
therapy claims of any class. Glaucoma therapy claims were Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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defined by therapeutic class plus generic code number (GCN) 
codes. GCNs are a system of unique numbers assigned by 
drug pricing service First DataBank to   medications accord-
ing to strength, formulation, route of administration, and 
size. The study population was further defined by requiring 
patients to have at least 12 months of uninterrupted prescrip-
tion refills of the index prostaglandin analog following the 
initial prescription. This was opera  tionalized as not having 
prescriptions for the other prostaglandin analogs during 
the year and having at least one prescription for the index 
prostaglandin analog in the fourth quarter of the follow-up 
period. Patients were required to be continuously enrolled 
during the 18-month period (six months prior to the first 
prostaglandin claim and the 12 months of follow-up), 
according to the PBM’s enrollment files. Patients who did 
not meet these requirements (sufficient prior claims data, 
uninterrupted use, and use of the index prostaglandin   analog 
during the fourth quarter of observation) were excluded 
from the study database. We considered that patients added 
an adjunctive medication, defined by therapeutic class plus 
GCN codes, if there was a sequential and subsequent refill 
of an adjunctive agent in the presence of continued refills 
for the index agent.
Literature review: resource  
use and cost inputs
The American Academy of Ophthalmology Preferred Prac-
tice Patterns for glaucoma suggest that follow-up care should 
be based on achievement of target IOP and the amount of 
disease progression,12 neither of which was available in the 
prescription database used for this study. Therefore, the base 
case analysis uses resource rates from a survey-based study25 
while sensitivity analyses explore visits as   recommended 
by other studies and guidelines.12,26 Since all patients in the 
model are assumed to undergo the same procedures and tests 
at their visits regardless of the prostaglandin analog they 
receive, the relatively small differences across studies in 
terms of the components of each visit have minimal impact 
on study findings.
At the initial visit, patients are assumed to have a level 
four (comprehensive) evaluation (CPT 92004). Follow-up 
visits are assumed to be level two (intermediate) visits 
(CPT 92012), with three follow-up visits   during the year 
(likely but not   necessarily at 30 and 90 days   following 
  initiation of the index therapy, and at 12 months). 
Two   additional follow-up visits are assumed to be asso-
ciated with the initiation and   monitoring of adjunctive 
medication among patients for whom it is prescribed. Thus 
patients who stay on   monotherapy are assumed to have one 
  comprehensive visit and three intermediate visits while those 
who require adjunctive therapy had one comprehensive visit 
and five intermediate visits. As the model only considered 
one year of treatment costs, it was not essential when in the 
year these visits occurred (ie, discounting based on timing 
was not   necessary); only the total number and type were 
relevant. Table 1 presents the procedures and diagnostic tests 
that comprise each visit as well as the costs used for each.
We used average wholesale price (AWP) for 2009 as the 
basis of prescription costs.27 The range of published AWPs 
for the prostaglandin analogs was fairly narrow ($80.53 to 
$82.67).27 For the prostaglandin analogs, the midpoint cost 
for the agents is used in the model because AWP is the best 
  publicly available estimate for the analysis. Further, the   number 
of prescriptions for prostaglandin analogs was expressed as 
Table 1 Unit costs
Resource Description/size Cost
initial visit CPT 92004 (comprehensive, new patient) plus weighted costs  
for visual field exam (92082), gonioscopy (92020), evaluation  
of optic disc (92135), optic nerve head photograph (92235),  
and fundus evaluation (92250) per Fremont et al25
$582.6128
Follow-up visit CPT 92012 (intermediate, established patient) and visual acuity  
exam (99173) per Fremont et al25
$117.6828
Prostaglandin analog 2.5 mL $81.6027
Fixed-combination dorzolamide  
2.0%/timolol 0.5%
5 mL $130.8027
Brimonidine 0.1% 5 mL $62.8027
Brinzolamide 1.0% 10 mL $91.3827
Timolol 0.25% 5 mL $17.9327
Other 5 mL $75.73  
(assumption)
Note: Costs are expressed in 2009 US$.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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2.5 mL size bottle equivalents, as this is the most common 
size found in the claims database and   represents approxi-
mately a 30–45 day supply when used per label in both eyes. 
For example, a 5 mL bottle was treated as two 2.5 mL bottles. 
The AWPs for adjunctive therapies were also reviewed in the 
Red Book.27 For the base case of the model, branded products 
were used, but sensitivity analyses explored lower costs. Days 
of use per bottle were based on data from these studies. The 
number of bottles required was rounded to the nearest tenth. 
Medical charges were estimated using the 75th percentile of 
physicians’ fees from a published benchmark.28 All the costs 
used in the model are presented in Table 1.
Analysis
The analysis identified patients by the prostaglandin 
  prescription they first filled (ie, the “index medication”)   during 
the study period. Gender was compared using a   chi-square test 
and age was compared using analysis of   variance (ANOVA) 
with Bonferroni’s correction for   multiple comparisons. The 
number of refills per year of each   prostaglandin was   calculated 
to use as an input to the   economic model. Median and mean 
number of days to initiation of adjunctive therapy were 
  calculated for each cohort, with the distribution of number 
of days examined to determine which measure to use in the 
model (ie, mean if the days were normally   distributed, median 
if they were not). The median numbers of days until patients 
added   adjunctive therapies were compared using the Wilcoxon 
rank sum test; mean times were compared using ANOVA. 
Statistical comparisons were conducted in SAS (v9.2; SAS 
Institute, Inc., Cary, NC).
Sensitivity analyses modified clinical and cost input 
parameters and explored the impact of assumptions on model 
findings. Two clinical inputs were varied. First, the proportion 
of patients remaining on monotherapy for the entire year was 
changed to the lowest and highest values among the initial 
treatments, that is, the proportion of patients remaining on 
monotherapy was changed to 77.5% (the base case value 
for bimatoprost) and then to 88.1% (the base case value for 
  BAK-free travoprost) for all treatments. Second, the days to 
initiating adjunctive therapy was varied in two ways: a) median 
number of days to the addition of adjunctive   medication was 
changed to the lowest and highest values among the treat-
ments and b) the mean number of days was substituted for 
the median. A number of cost-related variables were also sub-
jected to sensitivity analyses. The costs of treatments were var-
ied by assuming that the least and most expensive   adjunctive 
therapies were the only therapies used. Sensitivity analysis 
was also conducted on the cost of visits, using resource use 
estimates from other published sources.12,26 A minimum value 
for frequency of visits and resource use was estimated from 
the American Academy of   Ophthalmology Preferred Practice 
Patterns12 and assumed that patients were meeting IOP targets; 
the maximum value assumed that patients were not meeting 
IOP targets and that there was progression of disease. In addi-
tion, the 50th percentile of physicians’ fees was substituted 
for the 75th percentile.
Results
Figure 1 provides a flow chart of the patient selection 
  process for the retrospective cohort analysis. Of more than 
Participants who had 
12 months of uninterrupted 
use of index prostaglandin 
N = 12,296
Participants who 
switched to another 
prostaglandin 
N = 1,658
Participants who 
stopped using all 
glaucoma medications 
N = 13,855
Participants with no previous 
glaucoma medications prior to 
starting on a prostaglandin analog 
N = 27,809
Plan participants 
N = 75,000,000
Figure 1 Patient selection.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
441
Treatment costs among new initiators of prostaglandin analogs
75 million plan participants, 27,809 initiated treatment with 
a prostaglandin analog. Approximately 6% of these patients 
switched from their index prostaglandin analog to another 
glaucoma medication and about 50% of the patients stopped 
taking all glaucoma medications within the 12-month 
period. Of those switching, the primary alternative thera-
pies were another prostaglandin analog, beta-blocker, or 
fixed   combination therapy. The analysis examined only 
those newly initiating patients who remained on their 
initial   prostaglandin analog therapy for one year, which 
represents approximately 44% of the glaucoma patients 
newly initiating with prostaglandin analogs identified from 
the database.
Demographic characteristics of the newly initiating 
patients are presented in Table 2. More than half (55.4%) 
of the patients were women (P , 0.01). Mean age ranged 
from 63 to 65 years and was significantly different across 
groups (P , 0.0001, with BAK-free travoprost significantly 
different by less than two years from the other prostaglandin 
analogs).
The mean number of bottles per year of each prosta-
glandin (expressed as 2.5 mL bottle equivalents) was 
calculated, based on weighting findings from previous 
studies (8.7 for BAK-free travoprost, 9.0 for latanoprost, 
and 10.2 for   bimatoprost), and was used to calculate costs 
for   prostaglandin analogs. In the bimatoprost, latanoprost, 
and BAK-free travoprost treatment groups, 22.5%, 18.5%, 
and 11.9%, respectively, initiated adjunctive therapy during 
the course of the year at significantly different proportions 
(P , 0.0001, see Table 3). Patients on BAK-free travoprost 
were able to continue   without adjunctive therapy longer than 
patients treated with other prostaglandins. Figure 2 shows that 
the median numbers of days until patients added adjunctive 
therapies were 127 days for patients initiating therapy with 
BAK-free   travoprost, 64 days for bimatoprost, and 67 days 
for latanoprost (P = 0.0004, Wilcoxon rank sum test). The 
mean numbers of days to initiating adjunctive therapy 
were 144.9 days in the BAK-free travoprost group, 107.5 
for patients receiving bimatoprost, and 105.4 for patients 
receiving latanoprost. Mean time to initiating adjunctive 
therapy was also significantly different across the cohorts 
(P = 0.0002, ANOVA).
Figure 3 presents the primary findings from the analysis. 
Estimated annual costs for patients initiating therapy with 
BAK-free travoprost were lowest ($1,730; $964 medi-
cal and $766 pharmacy), with increasing annual costs for 
latanoprost ($1,803; $979 medical and $824 pharmacy), and 
bimatoprost ($1,945; $989 medical and $956 pharmacy). 
For all agents, visits comprised at least 50% of the total 
annual cost (50.8% for bimatoprost to 55.7% for BAK-free 
travoprost).
Results of sensitivity analyses are shown in Table 4. 
Findings remained consistent across univariate sensitivity 
analyses, with BAK-free travoprost having the lowest annual 
cost and bimatoprost having the highest cost in all scenarios. 
In the base case, the range of one-year costs across index medi-
cations was 12%; in univariate sensitivity analyses, it ranged 
from 8% to 16%. The single most influential   assumption was 
that all adjunctive therapy received was the most costly agent 
available. Bivariate sensitivity analyses resulted in differences 
in the range of 3% (highest rate of continued monotherapy 
and visit components based on AAO targets not met)12 to 18% 
across index medications (most costly adjunctive therapy and 
visit components based on Quigley estimates).26 In all cases, 
BAK-free travoprost remained the least costly option and 
bimatoprost the most costly option.
Discussion
This analysis adds to a growing body of literature finding 
  consistent differences in treatment patterns and costs for 
  glaucoma patients initiating treatment with prostaglandin 
  analogs with varying rates of adjunctive therapy use. Over 
a period of 18 months after initial availability of BAK-free 
  travoprost, patients initiating glaucoma treatment with this medi-
cation remained on monotherapy in greater proportions and for 
a longer duration compared to other prostaglandin analogs.
The early studies in this series included fewer patients as it 
takes time for patients to be transitioned to a new   formulation 
of an existing product. Although significant findings were 
detected in each study, there are benefits to pooling the data. 
Small variations are likely washed out, and the variance of 
continuous variables is narrower. For example, while the 
standard deviations of the mean time to adjunctive therapy 
remained large, they were considerably tighter in the pooled 
analysis. Using pooled results, with a larger population as 
the base for the model input parameters, may also suggest 
that the results are more generalizable.
Table 2 Demographic characteristics
Characteristic BAK-free  
travoprost
Bimatoprost Latanoprost
n 3,404 6,184 18,221
Age, mean ±  
standard deviation*
62.9 ± 13.3 64.5 ± 14.2 64.1 ± 14.4
gender, % female** 54.6% 53.7% 56.2%
Notes:  *P , 0.0001 across treatment groups (BAK-free travoprost significantly 
different from bimatoprost and latanoprost). **P , 0.01.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 3 Treatment patterns during follow-up period
Treatment pattern BAK-free  
travoprost
Bimatoprost Latanoprost
number remaining on index therapy (n) 1,210 2,644 8,442
remained on monotherapy (%)* 88.1% 77.5% 81.5%
required adjunctive therapy (%)* 11.9% 22.5% 18.5%
Type of adjunctive therapy:
  α2-adrenergic receptor agonist (%) 29.4% 27.1% 23.0%
  Beta-blocker (%) 28.9% 32.1% 40.1%
  Carbonic anhydrase inhibitor (%) 17.8% 15.2% 16.0%
    Fixed-combination beta-blocker/carbonic  
anhydrase inhibitor (%)
20.6% 22.1% 17.3%
  Other adjunctive therapy (%) 3.3% 3.5% 3.5%
Note: *P , 0.0001 (chi-square).
160
140
120
100
80
60
40
20
0
BAK-free travoprost Bimatoprost Latanoprost
Median
Mean
Figure 2 Days to initiating adjunctive therapy.
The use of a large claims database offers an important 
strength in terms of sample size. However, there are also 
disadvantages to the use of a pharmaceutical claims database 
without additional clinical input in terms of characterizing 
patients and/or prescribers.29 Patients are not randomized 
to treatment, although age and gender of the population 
reflected that of the general glaucoma   population30 and 
varied little across treatment groups. The reasons for 
  adding   adjunctive therapy, switching, or discontinuing 
therapies cannot be   surmised from a claims database alone. 
In   addition, claims databases report on prescriptions filled, 
but cannot be used as a definitive statement of adherence to 
therapy.31–34 Also affecting adherence and cost estimates is 
that there is no way to account for product samples, which 
one study identified as being received by 20% of patients.29 
We assumed that the use of samples would be similar across 
products studied in a database of this size. The population of 
prescribers may not accurately reflect national patterns, which 
could   misrepresent prescribing patterns. There are no data 
on the number of prescribers whose patients appear in the 
database, but as the data were from a large PBM, it is likely 
that there is a wide distribution of prescribers and practices. 
Finally, claims databases may contain coding biases or errors, 
although there is no reason to believe that these errors would 
be   different across index treatments; in addition, the claims 
in this   database were reviewed and adjudicated before the 
database was prepared for this analysis.
Beyond the limitations of a pharmaceutical claims data-
base, other assumptions may also have affected our study find-
ings. The study attempted to identify only patients who were 
new to therapy, although even a criterion as simple as this is 
difficult to implement.29 Also, based on the study methodology, 
patients could have had poor adherence but still have been 
included; patients in the cohort analysis were required to have 
a minimum of two prescriptions for the same prostaglandin 
analog filled during the follow-up period, but no attempt was Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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made to assess medication   possession ratio or to evaluate 
persistence with therapy over time. The subset of patients 
identified through this analysis may not be   representative of 
glaucoma patients in other aspects, although the nature of a pre-
scription claims database does not allow detailed exploration. 
For example, we could not detect other comorbid conditions, 
although it may have been possible to make some assumptions 
based on a thorough   evaluation of all prescription medications 
taken by each patient. All   assumptions about costs and resource 
utilization were explored through sensitivity analysis.
As with any economic model, findings are dependent 
on the strength of the assumptions. We have made every 
attempt to be transparent about the source of the input 
parameters, to use data from public and/or peer-reviewed 
sources, and we conducted thorough sensitivity analyses on 
the impact of these parameters. There will always remain 
uncertainty   inherent in models, but the difficulty of obtaining 
complete data on individual patients is often insurmountable. 
For example, data vendors tend to provide standardized 
costs rather than actual costs and even complete electronic 
$2,000
$1,800
$1,600
$1,400
$1,200
$1,000
$800
$600
$400
$200
$0
BAK-free 
travoprost
Bimatoprost Latanoprost
Visits
Index agent
Adjunctive therapies
Figure 3 Annual average cost per patient by category.
Table 4 Univariate sensitivity analyses
Parameter changed value  
to which it was changed
BAK-free travoprost Bimatoprost Latanoprost
Base case $1,730 $1,945 $1,803
Patients on monotherapy (%)
  Decreased to 77.5% for all $1,803 $1,945* $1,833
  increased to 88.1% for all $1,730* $1,861 $1,754
Days to adjunctive therapy
  Mean days to adjunctive therapy $1,726 $1,927 $1,791
  Decreased to 64 days for all $1,744 $1,945* $1,804
  increased to 144.9 days for all $1,726 $1,911 $1,779
Cost of therapies
  Changed to least costly adjunctive therapy $1,690 $1,855 $1,737
  Changed to most costly adjunctive therapy  $1,780 $2,067 $1,909
Cost of visits – alternative practice  
patterns and costs
  Based on Quigley et al26  $1,546 $1,761 $1,620
Based on American Academy of Ophthalmology12
  Targets met (minimum) $2,022 $2,237 $2,095
  Targets not met (maximum)  $4,269 $4,631 $4,434
  Based on 75th percentile UCr $2,021 $2,244 $2,100
Cost of prostaglandin analogs
  Actual costs $1,724 $1,937 $1,794
  round up to nearest whole number $1,734 $1,951 $1,810
Note: *no change from base case.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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health records cannot   consistently answer why patients 
  discontinue   treatment. Many studies report high rates of 
discontinuation with glaucoma treatment but provide no 
definitive answers,35–37 even when the interesting question of 
restarts during the observation period is considered.38
These findings showed that prostaglandin analogs with 
a greater proportion of patients remaining on monotherapy 
and a longer time to initiation of adjunctive agents had 
lower   first-year direct medical costs from a third party 
payer’s perspective. Additionally, while our resource use 
estimates assumed that follow-up visits to evaluate adjunctive 
  therapies would be coded as intermediate visits, up-coding 
(ie, coding these visits as comprehensive) could occur and 
this would   further differentiate products by rates of adjunctive 
therapy use. Accordingly, costs from the patient’s perspective 
(eg,   co-pays for visits and prescriptions) would also be lower 
with longer duration of monotherapy. Interestingly, there 
were no remarkable differences in the distribution of types of 
adjunctive therapies across treatment groups. Further study is 
needed to identify to what extent tolerability, specifically the 
absence of BAK, contributes to use of adjunctive medications 
either to supplement glaucoma treatment or to treat resultant 
co-morbidities such as dry eye or ocular surface disease.
There are important follow-up questions to these results. 
Why are there differences in rates of adjunctive therapy? 
Are there also differences in disease progression or the rate 
of   surgical interventions? What other patient   characteristics 
might affect use of adjunctive therapy, adherence with 
  therapy, or rates of disease progression? Unfortunately, the 
use of   pharmaceutical databases unaided by medical claims 
  information leaves these questions unanswered. We can 
  speculate that patients who do not experience OSD may 
be more likely to adhere to their prostaglandin treatment 
for longer periods of time, as has been shown with other 
  studies of BAK-free travoprost,14,16,39 but other variables 
may be   relevant. We are currently undertaking an analysis 
of a comprehensive health insurance claims database over a 
two-year time horizon in an effort to explore some of these 
questions.
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